Market Closed -
Nasdaq
16:30:00 2024-05-03 EDT
|
5-day change
|
1st Jan Change
|
35.78
USD
|
-1.35%
|
|
+6.62%
|
+66.26%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
221.4
|
377.3
|
234.3
|
27.67
|
775.2
|
1,441
|
-
|
-
|
Enterprise Value (EV)
1 |
221.4
|
377.3
|
234.3
|
27.67
|
435.6
|
803.5
|
1,108
|
1,365
|
P/E ratio
|
-3.12
x
|
-5.18
x
|
-4.75
x
|
-0.45
x
|
-0.44
x
|
-9.72
x
|
-10.9
x
|
-8.23
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
12.5
x
|
11.9
x
|
875
x
|
211
x
|
279
x
|
5,765
x
|
EV / Revenue
|
-
|
-
|
12.5
x
|
11.9
x
|
492
x
|
118
x
|
214
x
|
5,461
x
|
EV / EBITDA
|
-2.77
x
|
-4.69
x
|
-
|
-
|
-1.8
x
|
-6.09
x
|
-7.01
x
|
-
|
EV / FCF
|
-3.3
x
|
-4.71
x
|
-4.32
x
|
-
|
-4.36
x
|
-5.68
x
|
-8.15
x
|
-8.92
x
|
FCF Yield
|
-30.3%
|
-21.2%
|
-23.2%
|
-
|
-22.9%
|
-17.6%
|
-12.3%
|
-11.2%
|
Price to Book
|
3.7
x
|
2.7
x
|
2.79
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
1,159
|
1,917
|
1,973
|
2,460
|
36,021
|
40,279
|
-
|
-
|
Reference price
2 |
191.0
|
196.8
|
118.8
|
11.25
|
21.52
|
35.78
|
35.78
|
35.78
|
Announcement Date
|
20-02-24
|
21-03-18
|
22-03-08
|
23-03-02
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
18.74
|
2.329
|
0.886
|
6.817
|
5.167
|
0.25
|
EBITDA
1 |
-79.92
|
-80.48
|
-
|
-
|
-241.6
|
-132
|
-158
|
-
|
EBIT
1 |
-80.33
|
-81.48
|
-65.65
|
-84.78
|
-242.3
|
-164.5
|
-181.3
|
-224.8
|
Operating Margin
|
-
|
-
|
-350.33%
|
-3,640.23%
|
-27,347.97%
|
-2,412.58%
|
-3,508.44%
|
-89,904.56%
|
Earnings before Tax (EBT)
1 |
-78.25
|
-80.89
|
-65.66
|
-83.95
|
-338.8
|
-148.8
|
-178.6
|
-223.8
|
Net income
1 |
-78.25
|
-80.89
|
-65.8
|
-83.82
|
-338.8
|
-171.6
|
-181.7
|
-220.3
|
Net margin
|
-
|
-
|
-351.14%
|
-3,598.75%
|
-38,238.15%
|
-2,517.91%
|
-3,517.37%
|
-88,136.56%
|
EPS
2 |
-61.25
|
-38.00
|
-25.00
|
-24.75
|
-49.12
|
-3.680
|
-3.291
|
-4.346
|
Free Cash Flow
1 |
-67.18
|
-80.06
|
-54.29
|
-
|
-99.91
|
-141.5
|
-136
|
-153
|
FCF margin
|
-
|
-
|
-289.71%
|
-
|
-11,276.52%
|
-2,075.79%
|
-2,632.26%
|
-61,200%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
20-02-24
|
21-03-18
|
22-03-08
|
23-03-02
|
24-02-29
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
1.399
|
3.644
|
1.362
|
0.625
|
0.174
|
0.168
|
0.198
|
0.688
|
-
|
-
|
-
|
3.333
|
-
|
3.5
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-20.29
|
-20.44
|
-24.44
|
-22.42
|
-18.76
|
-19.16
|
-18.81
|
-159.2
|
-32.95
|
-45.91
|
-40.75
|
-38.29
|
-43.28
|
-42.14
|
-
|
Operating Margin
|
-1,450.54%
|
-560.98%
|
-1,794.49%
|
-3,587.68%
|
-10,778.74%
|
-11,405.95%
|
-9,497.98%
|
-23,146.22%
|
-
|
-
|
-
|
-1,148.82%
|
-
|
-1,203.91%
|
-
|
Earnings before Tax (EBT)
1 |
-20.28
|
-20.42
|
-24.44
|
-22.31
|
-18.44
|
-18.78
|
-18.46
|
-217.1
|
-40.1
|
-63.18
|
-37.88
|
-34.85
|
-40.77
|
-39.3
|
-
|
Net income
1 |
-20.31
|
-20.45
|
-24.44
|
-22.32
|
-18.23
|
-18.82
|
-18.42
|
-217.1
|
-40.11
|
-63.18
|
-42.32
|
-39.99
|
-45.16
|
-44.15
|
-
|
Net margin
|
-1,451.54%
|
-561.09%
|
-1,794.13%
|
-3,571.68%
|
-10,479.31%
|
-11,203.57%
|
-9,304.04%
|
-31,552.47%
|
-
|
-
|
-
|
-1,199.82%
|
-
|
-1,261.53%
|
-
|
EPS
2 |
-7.750
|
-7.750
|
-9.250
|
-6.750
|
-4.750
|
-4.500
|
-5.000
|
-56.75
|
-9.340
|
-4.050
|
-1.167
|
-0.9367
|
-0.9900
|
-0.9483
|
-0.4000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-11-04
|
22-03-08
|
22-05-05
|
22-08-04
|
22-11-03
|
23-03-02
|
23-05-11
|
23-08-11
|
23-11-09
|
24-02-29
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
340
|
638
|
333
|
76
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-67.2
|
-80.1
|
-54.3
|
-
|
-99.9
|
-142
|
-136
|
-153
|
ROE (net income / shareholders' equity)
|
-123%
|
-80.9%
|
-58.8%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-97.3%
|
-66.1%
|
-48.5%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
80.46
|
122.4
|
135.8
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
51.70
|
72.90
|
42.50
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.49
|
4.28
|
0.57
|
0.04
|
-
|
3
|
1.5
|
2.5
|
Capex / Sales
|
-
|
-
|
3.06%
|
1.63%
|
-
|
44.01%
|
29.03%
|
1,000%
|
Announcement Date
|
20-02-24
|
21-03-18
|
22-03-08
|
23-03-02
|
24-02-29
|
-
|
-
|
-
|
Last Close Price
35.78
USD Average target price
43.14
USD Spread / Average Target +20.58% Consensus |
1st Jan change
|
Capi.
|
---|
| +66.26% | 1.44B | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +6.79% | 14.16B | | +38.61% | 12.63B |
Bio Therapeutic Drugs
|